AAIC 2025 Abstract
Early Detection and Monitoring of Amyloid‐Related Imaging Abnormalities in Monoclonal Antibody Therapy Using Generalized Diffusion Basis Spectrum Imaging (g‐DBSI): A Pilot Study
By Meng Jiang, Nelly Joseph-Mathurin, Yong Wang, Show 16 more authorsthe Dominantly Inherited Alzheimer Network Trials Unit Study Team
Trial in peopleBiomarkers
Abstract
Background: Amyloid‐Related Imaging Abnormalities (ARIA), characterized by vasogenic edema or sulcal effusions (ARIA‐E) or hemorrhagic lesions (microhemorrhages, superficial siderosis, or, rarely, microhemorrhages) (ARIA‐H), remain a significant challenge in monoclonal antibody (mAb) therapy for AD (1).
